Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status:
Terminated
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The objective of this active-drug Extension Study is to evaluate the continuing safety and
efficacy of ONO-4641 (MSC2430913A) in subjects with relapsing-remitting multiple sclerosis
(RRMS) who have completed an initial 26-week Core Study (ONO-4641POU006 [NCT01081782]).
Phase:
Phase 2
Details
Lead Sponsor:
EMD Serono
Collaborators:
Merck KGaA Merck KGaA, Darmstadt, Germany Ono Pharmaceutical Co. Ltd